Nonsurgical treatment of advanced metastatic cervical disease in cancer of the larynx.
Historically, patients with advanced cervical adenopathy (N2 or N3) have between a 20 and 30% chance of surviving their disease at 5 years from treatment. Despite attempts at more aggressive surgical resection, including resection and reconstruction of the carotid artery, patients with advanced cervical adenopathy remain at the highest risk for the development of local recurrences and distant metastases. This chapter will review the current limitations of surgical resectability for advanced neck disease, discuss the evolution of combined chemoradiation therapy for these patients, and finally present promising recent technological advances in radiation oncology which will have significant impact on the treatment of these patients.
Petruzzelli
G J
GJ
Department of Otolaryngology-Head and Neck Surgery, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, Ill. 60153, USA. gpetruz@wpo.it.luc.edu
Emami
B
B
D003131:Combined Modality Therapy; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology* / Q000628:therapy*; D008198:Lymph Nodes / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D009333:Neck / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed